Trial | NCT02902016  Report issue

Title

Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies
Modulation of Lactase Expression by a New Synthetic PPARgamma Ligand in Ex-vivo Cultures of Duodenal Biopsies

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    22
This study is designed to assess the effect of a new PPARgamma modulator on the expression and activity of the lactase enzyme in human intestinal epithelial cells. Based on their previous experimental results, the investigators hypothesized that modulating intestinal PPARgamma activity is a new pharmacological mechanism allowing the control of lactase expression and activity in the gut
Study Started
Jul 16
2015
Primary Completion
Sep 30
2017
Study Completion
Sep 30
2017
Last Update
Oct 17
2018

Drug GED

Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).

Lactase expression induction by GED Experimental

Criteria 

Inclusion Criteria:

Subjects undergoing gastroduodenal endoscopy for digestive cancer screening
Subjects undergoing gastroduodenal endoscopy for ulcerative gastroduodenal diseases
Subjects undergoing gastroduodenal endoscopy for epigastric pains
Subjects undergoing gastroduodenal endoscopy for gastroesophageal reflux diseases

Exclusion Criteria:

Subjects with macroscopic duodenal lesions detected at endoscopy
Subjects suffering from coeliac disease
Subjects suffering from atrophic gastritis
Subjects who use anticoagulant
Pregnancy or breast feeding
No Results Posted